Special Issue

Innovations and Translational Approaches in Stroke Research

Message from the Guest Editors

Our Special Issue aims to accommodate a broad spectrum of topics; including novel pathogenesis mechanisms that underlie these acute conditions; translational research; a pivotal bridge between basic science findings and their clinical applications: the role of biomaterials in stroke research, especially those that promote neurorestoration; and the discovery of specific biomarkers and diagnostic methods for stroke. The world of neuropharmacology is buzzing with innovative drug discoveries and developments, all aimed at the prevention and treatment of stroke. We therefore also welcome contributions on biopharmaceutical approaches that span biologics, biosimilars, and nanobiotechnological innovations in stroke therapy, from targeted nanomedicine, nano-scaffolding, and biosensors to gene and cell therapy. We invite authors to contribute their research and insights, helping to shape our understanding of stroke.

- acute ischemic stroke
- hemorrhagic stroke
- biomaterials in stroke
- stroke diagnosis
- drug development for stroke
- biopharmaceutical approaches
- nanobiotechnology in stroke therapy
- gene and cell therapy
- nano-scaffolding

Guest Editors

Dr. Ştefan Strilciuc

Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania

Prof. Dr. Dafin Fior Mureşanu

Department of Neurosciences, Iuliu Hațieganu University of Medicine and Pharmacy, No. 8 Victor Babeş Street, 400012 Cluj-Napoca, Romania

Deadline for manuscript submissions

closed (30 November 2024)



Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/183989

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).